Dabigatran: A Primer for Neurosurgeons

详细信息    查看全文

• 作者：Jennifer E. Fugate¹ ; Alejandro A. Rabinstein¹ ; Robert D. McBane² ; Giuseppe Lanzino³ ; ^{lanzino.giuseppe@mayo.edu}
• 关键词：Anticoagulants ; Benzimidazoles ; Blood coagulation ; Direct thrombin inhibitors ; Intracranial hemorrhages ; Perioperative period
• 刊名：World Neurosurgery
• 出版年：2013
• 出版时间：January, 2013
• 年：2013
• 卷：79
• 期：1
• 页码：154-158
• 全文大小：999 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferencesl version=""1.0"" encoding=""UTF-8""?>

lass=""h4"">Objective

This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.

lass=""h4"">Methods

We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).

lass=""h4"">Results

Dabigatran has the advantage of providing rapid and steady anticoagulation without requiring laboratory monitoring. However, the fact that no practical, reliable method of monitoring of the anticoagulant effects is available constitutes a challenge when contemplating urgent neurosurgical procedures in patients treated with this medication. Although the risk of intracranial hemorrhage with dabigatran was lower than with warfarin in the large trial leading to the approval of the drug, the management of these complications may be problematic because there is no current antidote.

lass=""h4"">Conclusions

We present a basic overview of dabigatran, discuss the implications for the perioperative management of patients taking this new anticoagulant, and offer recommendations for the management of intracranial hemorrhage related to this drug.